Celldex Therapeutics Statistics
Total Valuation
CLDX has a market cap or net worth of $2.38 billion. The enterprise value is $1.98 billion.
| Market Cap | 2.38B |
| Enterprise Value | 1.98B |
Important Dates
The next estimated earnings date is Thursday, May 2, 2024, after market close.
| Earnings Date | May 2, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CLDX has 64.42 million shares outstanding. The number of shares has increased by 3.33% in one year.
| Shares Outstanding | 64.42M |
| Shares Change (YoY) | +3.33% |
| Shares Change (QoQ) | +10.17% |
| Owned by Insiders (%) | 0.35% |
| Owned by Institutions (%) | 96.79% |
| Float | 52.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 349.11 |
| Forward PS | 634.47 |
| PB Ratio | 5.60 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 287.93 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.87, with a Debt / Equity ratio of 0.01.
| Current Ratio | 13.87 |
| Quick Ratio | 13.69 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -45.00% and return on invested capital (ROIC) is -35.80%.
| Return on Equity (ROE) | -45.00% |
| Return on Assets (ROA) | -41.30% |
| Return on Capital (ROIC) | -35.80% |
| Revenue Per Employee | $43,019 |
| Profits Per Employee | -$883,931 |
| Employee Count | 160 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.59% in the last 52 weeks. The beta is 1.56, so CLDX's price volatility has been higher than the market average.
| Beta (1Y) | 1.56 |
| 52-Week Price Change | +6.59% |
| 50-Day Moving Average | 41.95 |
| 200-Day Moving Average | 34.32 |
| Relative Strength Index (RSI) | 37.33 |
| Average Volume (30 Days) | 944,512 |
Short Selling Information
The latest short interest is 6.56 million, so 10.18% of the outstanding shares have been sold short.
| Short Interest | 6.56M |
| Short Previous Month | 5.90M |
| Short % of Shares Out | 10.18% |
| Short % of Float | 12.43% |
| Short Ratio (days to cover) | 5.50 |
Income Statement
In the last 12 months, CLDX had revenue of $6.88 million and -$141.43 million in losses. Loss per share was -$2.92.
| Revenue | 6.88M |
| Gross Profit | 6.88M |
| Operating Income | -154.54M |
| Pretax Income | -141.43M |
| Net Income | -141.43M |
| EBITDA | -138.42M |
| EBIT | -141.43M |
| Loss Per Share | -$2.92 |
Balance Sheet
The company has $423.60 million in cash and $2.54 million in debt, giving a net cash position of $421.06 million or $6.54 per share.
| Cash & Cash Equivalents | 423.60M |
| Total Debt | 2.54M |
| Net Cash | 421.06M |
| Net Cash Per Share | $6.54 |
| Equity / Book Value | 429.17M |
| Book Value Per Share | 6.66 |
| Working Capital | 400.57M |
Cash Flow
In the last 12 months, operating cash flow was -$107.29 million and capital expenditures -$1.82 million, giving a free cash flow of -$109.11 million.
| Operating Cash Flow | -107.29M |
| Capital Expenditures | -1.82M |
| Free Cash Flow | -109.11M |
| FCF Per Share | -$2.25 |
Margins
Gross margin is 100.00%, with operating and profit margins of -2,245.27% and -2,054.76%.
| Gross Margin | 100.00% |
| Operating Margin | -2,245.27% |
| Pretax Margin | -2,054.76% |
| Profit Margin | -2,054.76% |
| EBITDA Margin | -2,011.06% |
| EBIT Margin | -2,054.76% |
| FCF Margin | -1,585.20% |
Dividends & Yields
CLDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.33% |
| Shareholder Yield | -3.33% |
| Earnings Yield | -5.89% |
| FCF Yield | -4.54% |
Analyst Forecast
The average price target for CLDX is $66.00, which is 78.28% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $66.00 |
| Price Target Difference | 78.28% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 124.56% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on February 11, 2019. It was a reverse split with a ratio of 1:15.
| Last Split Date | Feb 11, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
CLDX has an Altman Z-Score of 35.39 and a Piotroski F-Score of 3.
| Altman Z-Score | 35.39 |
| Piotroski F-Score | 3 |